Company / Operating Cash Flow per Share
Jazz Pharmaceuticals Operating Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
$22.36
FY2025
5-year range
$13.82 / $22.42
FY2021-FY2025
Trend
-0.3%
vs FY2024
Sector context
#4 of 212
Health Care
What the data says
Among 212 Health Care companies, Jazz Pharmaceuticals is in the top 2% for operating cash flow per share. Operating Cash Flow per Share has fluctuated over the past 10 years, ranging from $6.65 in FY2016 to $22.42 in FY2024.
Based on SEC 10-K filings.
22.36 in FY2025 with a 5-year CAGR of +9.5%. Top quartile in the Health Care sector.
Improved from $17.27 to $22.36 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- +15.3%
- 5-Year CAGR
- +9.5%
- 10-Year CAGR
- -
Sector benchmark
+323.8% above sector average
Key checks
Key Insights
- In FY2025, operating cash flow per share decreased 0.3% year-over-year.
- Ranks #4 out of 212 companies in the Health Care sector.
- Peak operating cash flow per share was recorded in FY2024.
- Lowest operating cash flow per share in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 0.66 (distress zone, below 1.8 threshold)
- Negative profit margin: -8.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $22.36 | -0.3% |
| FY2024 | $22.42 | +29.8% |
| FY2023 | $17.27 | +18.3% |
| FY2022 | $14.60 | +5.6% |
| FY2021 | $13.82 | -2.9% |
| FY2020 | $14.23 | +18.5% |
| FY2019 | $12.01 | +19.4% |
| FY2018 | $10.06 | -13.2% |
| FY2017 | $11.59 | +74.3% |
| FY2016 | $6.65 | -24.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026